AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
DABIGATRAN ETEXILATE
21 registrations across 4 African markets— 21 active
Markets with DABIGATRAN ETEXILATE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| DAXIMRA 75 CAPSULE; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED [OTL] | active | Dec 2030 |
| DAXIMRA 110 CAPSULE; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED [OTL] | active | Dec 2030 |
| DAXIMRA 150 CAPSULE; ORAL | 🇿🇼Zimbabwe | MYLAN LABORATORIES LIMITED | active | Dec 2030 |
| Hetsolid 110 mg Capsules Capsule | 🇳🇬Nigeria | Hetero Labs Nigeria Limited | active | Apr 2030 |
| Hetsolid 75 mg Capsules Capsule | 🇳🇬Nigeria | Hetero Labs Nigeria Limited | active | Apr 2030 |
| Hetsolid 150 mg Capsules Capsule | 🇳🇬Nigeria | Hetero Labs Nigeria Limited | active | Apr 2030 |
| HETSOLID 150 CAPSULES | 🇷🇼Rwanda | M/s Hetero Labs Limited | active | Aug 2029 |
| HETSOLID 110 Capsules | 🇷🇼Rwanda | M/s Hetero Labs Limited | active | Aug 2029 |
| HETSOLID 75 Capsules | 🇷🇼Rwanda | M/s Hetero Labs Limited | active | Aug 2029 |
| DABIFIB 150 CAPSULE | 🇿🇼Zimbabwe | MSN LABORATORIES PRIVATE LIMITED | active | Dec 2027 |
| DABIFIB 110 CAPSULE | 🇿🇼Zimbabwe | MSN LABORATORIES PRIVATE LIMITED | active | Dec 2027 |
| DABIFIB 75 CAPSULE | 🇿🇼Zimbabwe | MSN LABORATORIES PRIVATE LIMITED | active | Dec 2027 |
| HETSOLID 110 CAPSULE | 🇿🇼Zimbabwe | HETERO LABS LTD | active | Dec 2027 |
| HETSOLID 150 CAPSULE | 🇿🇼Zimbabwe | HETERO LABS LTD | active | Dec 2027 |
| HETSOLID 75 CAPSULE | 🇿🇼Zimbabwe | HETERO LABS LTD | active | Dec 2027 |
| DABIFIB 150 capsule | 🇹🇿Tanzania | MSN Laboratories Private Limited | active | — |
| HETSOLID 150 capsule | 🇹🇿Tanzania | Hetero Labs Limited | active | — |
| DABIFIB 75 Capsules | 🇹🇿Tanzania | MSN Laboratories Private Limited | active | — |
| HETSOLID 75 capsule | 🇹🇿Tanzania | Hetero Labs Limited | active | — |
| HETSOLID 110 capsule | 🇹🇿Tanzania | Hetero Labs Limited | active | — |
| DABIFIB 110 capsule | 🇹🇿Tanzania | MSN Laboratories Private Limited | active | — |
DABIGATRAN ETEXILATE in Africa — Regulatory Overview
DABIGATRAN ETEXILATE is registered across 4 African markets with 21 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zimbabwe, Tanzania, Nigeria, Rwanda. AfricaRegulatory refreshes this data daily from official government sources.
Of the 21 registrations, 21 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.